Suppr超能文献

肌肉减少症概述:患病率及临床影响的事实与数据

An overview of sarcopenia: facts and numbers on prevalence and clinical impact.

作者信息

von Haehling Stephan, Morley John E, Anker Stefan D

出版信息

J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):129-133. doi: 10.1007/s13539-010-0014-2. Epub 2010 Dec 17.

Abstract

Human muscle undergoes constant changes. After about age 50, muscle mass decreases at an annual rate of 1-2%. Muscle strength declines by 1.5% between ages 50 and 60 and by 3% thereafter. The reasons for these changes include denervation of motor units and a net conversion of fast type II muscle fibers into slow type I fibers with resulting loss in muscle power necessary for activities of daily living. In addition, lipids are deposited in the muscle, but these changes do not usually lead to a loss in body weight. Once muscle mass in elderly subjects falls below 2 standard deviations of the mean of a young control cohort and the gait speed falls below 0.8 m/s, a clinical diagnosis of sarcopenia can be reached. Assessment of muscle strength using tests such as the short physical performance battery test, the timed get-up-and-go test, or the stair climb power test may also be helpful in establishing the diagnosis. Sarcopenia is one of the four main reasons for loss of muscle mass. On average, it is estimated that 5-13% of elderly people aged 60-70 years are affected by sarcopenia. The numbers increase to 11-50% for those aged 80 or above. Sarcopenia may lead to frailty, but not all patients with sarcopenia are frail-sarcopenia is about twice as common as frailty. Several studies have shown that the risk of falls is significantly elevated in subjects with reduced muscle strength. Treatment of sarcopenia remains challenging, but promising results have been obtained using progressive resistance training, testosterone, estrogens, growth hormone, vitamin D, and angiotensin-converting enzyme inhibitors. Interesting nutritional interventions include high-caloric nutritional supplements and essential amino acids that support muscle fiber synthesis.

摘要

人体肌肉会持续发生变化。大约在50岁以后,肌肉质量以每年1%-2%的速度下降。在50岁至60岁之间,肌肉力量下降1.5%,之后每年下降3%。这些变化的原因包括运动单位失神经支配,以及快速型II型肌纤维净转化为慢速型I型纤维,从而导致日常生活活动所需的肌肉力量丧失。此外,脂质会沉积在肌肉中,但这些变化通常不会导致体重减轻。一旦老年受试者的肌肉质量低于年轻对照队列平均值的2个标准差,且步速低于0.8米/秒,即可做出肌肉减少症的临床诊断。使用简短体能状况量表测试、定时起立行走测试或爬楼梯功率测试等方法评估肌肉力量,也可能有助于确诊。肌肉减少症是肌肉质量丧失的四大主要原因之一。据估计,平均而言,60至70岁的老年人中有5%-13%受肌肉减少症影响。80岁及以上人群的这一比例增至11%-50%。肌肉减少症可能导致身体虚弱,但并非所有肌肉减少症患者都身体虚弱——肌肉减少症的发生率约为身体虚弱的两倍。多项研究表明,肌肉力量下降的受试者跌倒风险显著升高。肌肉减少症的治疗仍然具有挑战性,但使用渐进性抗阻训练、睾酮、雌激素、生长激素、维生素D和血管紧张素转换酶抑制剂已取得了有前景的结果。有趣的营养干预措施包括高热量营养补充剂和支持肌纤维合成的必需氨基酸。

相似文献

1
An overview of sarcopenia: facts and numbers on prevalence and clinical impact.
J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):129-133. doi: 10.1007/s13539-010-0014-2. Epub 2010 Dec 17.
2
From muscle wasting to sarcopenia and myopenia: update 2012.
J Cachexia Sarcopenia Muscle. 2012 Dec;3(4):213-7. doi: 10.1007/s13539-012-0089-z.
3
Possible Sarcopenia and Impact of Dual-Task Exercise on Gait Speed, Handgrip Strength, Falls, and Perceived Health.
Front Med (Lausanne). 2021 Apr 16;8:660463. doi: 10.3389/fmed.2021.660463. eCollection 2021.
4
Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women.
J Gerontol A Biol Sci Med Sci. 2002 Dec;57(12):M772-7. doi: 10.1093/gerona/57.12.m772.
6
Effects of whey protein nutritional supplement on muscle function among community-dwelling frail older people: A multicenter study in China.
Arch Gerontol Geriatr. 2019 Jul-Aug;83:7-12. doi: 10.1016/j.archger.2019.03.012. Epub 2019 Mar 17.
8
Sarcopenia and frailty in geriatric patients: implications for training and prevention.
Z Gerontol Geriatr. 2004 Feb;37(1):2-8. doi: 10.1007/s00391-004-0203-8.
10
Vitamin B12 deficiency might be related to sarcopenia in older adults.
Exp Gerontol. 2017 Sep;95:136-140. doi: 10.1016/j.exger.2017.05.017. Epub 2017 May 23.

引用本文的文献

1
RNA signaling in skeletal muscle: the central role of microRNAs and exosomal microRNAs.
Front Cell Dev Biol. 2025 Aug 4;13:1639123. doi: 10.3389/fcell.2025.1639123. eCollection 2025.
2
A review of the status of sarcopenia in elderly hospitalized patients.
Medicine (Baltimore). 2025 Jul 11;104(28):e43365. doi: 10.1097/MD.0000000000043365.
5
Correlation between iron accumulation and sarcopenia in middle-aged and elderly populations.
BMC Musculoskelet Disord. 2025 Jul 4;26(1):638. doi: 10.1186/s12891-025-08890-8.
8
The Role of Adipokines in Spinal Disease: A Narrative Review.
JOR Spine. 2025 Jun 3;8(2):e70083. doi: 10.1002/jsp2.70083. eCollection 2025 Jun.

本文引用的文献

1
Cachexia as a major underestimated and unmet medical need: facts and numbers.
J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):1-5. doi: 10.1007/s13539-010-0002-6. Epub 2010 Oct 26.
2
Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.
J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):7-8. doi: 10.1007/s13539-010-0003-5. Epub 2010 Oct 26.
3
Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training.
J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):9-21. doi: 10.1007/s13539-010-0007-1. Epub 2010 Oct 26.
5
A prospective study of the associations between 25-hydroxyvitamin D, sarcopenia progression and physical activity in older adults.
Clin Endocrinol (Oxf). 2011 Jan;74(1):138; author reply 139. doi: 10.1111/j.1365-2265.2010.03888.x.
6
Optimal management of sarcopenia.
Clin Interv Aging. 2010 Sep 7;5:217-28. doi: 10.2147/cia.s11473.
9
An update on dual-energy x-ray absorptiometry.
Semin Nucl Med. 2010 Jan;40(1):62-73. doi: 10.1053/j.semnuclmed.2009.08.001.
10
Sarcopenia: etiology, clinical consequences, intervention, and assessment.
Osteoporos Int. 2010 Apr;21(4):543-59. doi: 10.1007/s00198-009-1059-y. Epub 2009 Sep 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验